BERKELEY, Calif. — Renasant Bio (Renasant), announced its launch today to advance next-generation disease-modifying treatments for autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cause of end-stage renal failure. Renasant is developing a pipeline of oral small molecule corrector and first-in-class potentiator therapies that directly target the underlying biology...

Tosse, France – After decades of limited progress—owing to the difficulty of treating the disease and resultant market risk—glioblastoma research is entering a new phase spurred by smarter trials, targeted funding and renewed interest from companies like Merck and Jazz Pharmaceuticals. Glioblastoma, a deadly brain cancer, is notoriously difficult to...

NEWPORT BEACH, Calif. and EDMONTON, AB — CureDuchenne Ventures announced an initial $1M investment in Entos Pharmaceuticals Inc (Entos), a biotech company that develops genetic medicines utilizing its non-viral, redosable Fusogenix PLV delivery platform. Entos will use this funding to create a muscle-targeting therapeutic to deliver full-length dystrophin for the treatment of Duchenne...